Clinical Development Nurses Protein 
pharmaphorum
DECEMBER 23, 2022
There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Side effects and cost implications. Professional reception of the findings.
The Pharma Data
APRIL 8, 2021
Roche will present data from five studies from the EVRYSDI clinical development programme, which was designed to represent a broad spectrum of people living with SMA. The full range of data from Roche’s clinical development programme in neuroscience being presented at 2021 AAN include: Medicine and/or Therapeutic Area.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JANUARY 5, 2021
Developed by Ellume Therapeutics , the test is a rapid, lateral flow antigen test, which involves passing a liquid sample along a surface with detection antibodies. The test identifies SARS-CoV-2 protein fragments from nasal swab samples. As a result, nurses were deployed more broadly and became more involved in supporting a study. “[It]
The Pharma Data
DECEMBER 17, 2020
Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication. patients under an Emergency Use Authorization, and we also continue a robust clinical development program.” “The investigational cocktail is now available to indicated high-risk U.S.
The Pharma Data
DECEMBER 29, 2020
Senior Vice President and Head of Global Clinical Development at Regeneron. The development and manufacturing of the antibody cocktail has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S.
The Pharma Data
AUGUST 11, 2020
We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early- to mid-stage development. Serious Adverse Reactions.
The Pharma Data
AUGUST 11, 2020
We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early- to mid-stage development. Serious Adverse Reactions.
Expert insights. Personalized for you.
52 
Let's personalize your content